Alzheimer’s Association Applauds CMS Decision to Cover PET Imaging for Alzheimer’s Disease Diagnosis
A valuable Alzheimer’s disease diagnostic tool will now be more accessible across the country thanks to a policy change today by the Centers for Medicare & Medicaid Services (CMS). The Alzheimer’s Association applauds CMS for taking action to expand coverage of brain amyloid positron emission tomography (PET) imaging for the diagnosis of Alzheimer’s disease.
Duran Duran’s Andy Taylor was diagnosed with stage 4 prostate cancer in 2018 but is now “asymptomatic” after receiving a new and innovative cancer treatment. The musician was administered Lutetium-177, a type of radioactive treatment that targets cancer cells. In an interview with The Times, he said: “I was classified as palliative, end-of-life care. Now I’m not; I’m asymptomatic.”
The PET diagnostic imaging agent, flotufolastat F 18 injection (Posluma; formerly 18F-rhPSMA-7.3) has been approved by the FDA for the identification of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer.
Northern California PET Imaging Center, a global leader in precision cancer imaging using PET/CT Technology, announced the appointment of Bradley Schmidt as Chief Executive Officer.